期刊文献+

帕罗西汀对抑郁症患者血浆中P物质和神经肽Y的影响 被引量:9

下载PDF
导出
摘要 目的:探讨抑郁症患者血浆中P物质(SP)和神经肽Y(NPY)含量改变以及帕罗西汀的干预作用。方法:对30例抑郁症患者(抑郁症组)应用帕罗西汀治疗6周,分别于治疗前和治疗后第6周末采用ELISA法测定血浆中SP和NPY含量;同时进行汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评定症状变化。以30名健康体检者为对照组。结果:抑郁症组患者治疗前血浆SP含量明显高于对照组,NPY含量明显低于对照组(均P<0.05)。经帕罗西汀治疗6周后,患者血浆SP含量明显降低,NPY含量明显升高(均P<0.05),且患者HAMD及HAMA总分均较治疗前明显降低(均P<0.01)。结论:血浆SP和NPY含量改变可能是抑郁症病理生理的环节之一,血浆NPY含量增加和SP含量降低可能是帕罗西汀治疗抑郁症的另外一种机制。
作者 杨敏
出处 《实用医学杂志》 CAS 2008年第6期1042-1043,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献8

  • 1Mantyh P W. Neurobiology of substance P and the NK1 receptor [J]. J Clin Psychiatry., 2002,63(Suppl 11 ) :6-10.
  • 2Redrobe J P, Dumont Y, Quirlon R. Neuropeptide Y (NPY) and depression:from animal studies to the human condition [J]. Life Sci, 2002,71 (25) : 2921-2937.
  • 3杨斌,王有德,张兰,叶兰仙,张玉堂,刘建斌,陈雪红.抑郁症患者血浆P物质含量变化及其相关性研究[J].中华精神科杂志,2006,39(2):78-80. 被引量:31
  • 4杨斌,王有德,叶兰仙,张兰,张玉堂,刘建斌,陈雪红.抑郁症患者血浆神经肽Y含量变化及其影响因素[J].中国临床康复,2006,10(46):106-108. 被引量:20
  • 5Cheng J T, Chang C L, Tsai C L. Inhibitory efect of neuropeptide Y (NPY) on the in vitro activity of tyrosine hydroxylase [J]. Neurosci Lett, 1994, 167( 1-2): 117-120.
  • 6Heilig M, Zachrisson O, Thorsell A, et al. Decreased cere brospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism [J]. Psychiatr Res, 2004,38 (2):113-121.
  • 7Jimenez Vasquez P A, Salmi P, Ahlenius S, et al. Neuropeptide Y in brains of the Flinders Sensitive Line rat,a model of depreaion. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion [ J ]. Behav Brain Res, 2000, 111 ( 1- 2) : 115-123.
  • 8Herpfer I, Lieb K. Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders [J]. Wodd J Biol Psychiatry, 2003,4(2) :56-63.

二级参考文献24

  • 1Blier P, Gobbi G, Haddjeri N, et al. Impact of substance P receptor antagonism on the semtonin and norepinephrine systems : relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci, 2004,29:208-218.
  • 2Kombian SB, Ananthalakshmi KV, Parvathy SS, et al. Dopamine and adenosine mediate substance P-induced depression of evoked IPSCs in the rat nucleus accumbens in vitro. Eur J Neurosci, 2003,18:303-311.
  • 3Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry, 2002, 63 Suppl 11:6-10.
  • 4De Wied D, Sigling HO. Neutropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res, 2002, 4:453-468.
  • 5Datar P, Srivastava S, Coutinho E, et al. Substance P: structure,function, and therapeutics. Curr Top Med Chem, 2004, 4:75-103.
  • 6Herpfer I, Lieb K. Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry, 2003, 4:56-63.
  • 7Bondy B, Baghai TC, Minor C, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry,2003, 53:538-542.
  • 8Duffy RA. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs, 2004, 9:9-21.
  • 9Holmes A, Heilig M, Rupniak NM, et al. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci, 2003, 24:580-588.
  • 10Santarelli L, Saxe MD. Substance P antagonists: meet the new drugs, same as the old drugs :insights from transgenic animal models.CNS Spectr, 2003, 8:589-596.

共引文献42

同被引文献110

引证文献9

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部